Scheduled for Tuesday, March 9, 2020, from 11:00 AM ET to 12:00 PM ET • Hosted by the AST Infectious Disease Community of Practice (IDCOP)
In this article:
The role of antiviral prophylaxis or rituximab therapy for prevention of PTLD in SOT recipients is controversial. In a nationwide cohort, we assessed the incidence, presentation, and outcome of histologically proven PTLD. We included 4765 patients with a follow‐up duration of 23 807 person‐years (py). Fifty‐seven PTLD cases were identified; 39 (68%) were EBV positive (EBV+ PTLD)... However, none of the patients (0/191) who received a rituximab‐containing induction treatment experienced PTLD, but 57 of 4574 patients without rituximab induction developed PTLD. In an adjusted restricted mean survival time model, PTLD‐free survival was significantly longer (0.104 years [95% CI 0.077–0.131]) in patients receiving rituximab as induction treatment. This study provides novel data on the association of rituximab induction and reduced risk for PTLD.
Laura Walti, MD; Inselspital, Bern University Hospital; Bern, Switzerland
Upton Allen; MBBS, MSc, FAAP; SickKids, University of Toronto; Toronto, Canada
AST/AJT Journal Clubs are free, but registration is required.